These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 25034619)

  • 1. Investigation of the relationship between a starting dose in first-in-human studies and no observed adverse effect level in nonclinical studies.
    Sato A; Narukawa M
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):770-6. PubMed ID: 25034619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A brief survey of first-in-human studies.
    Wexler D; Bertelsen KM
    J Clin Pharmacol; 2011 Jul; 51(7):988-93. PubMed ID: 20671293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microdosing Studies in Children: A US Regulatory Perspective.
    Roth-Cline M; Nelson RM
    Clin Pharmacol Ther; 2015 Sep; 98(3):232-3. PubMed ID: 26095312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences between Japan and the United States in dosages of drugs recently approved in Japan.
    Nakashima K; Narukawa M; Kanazu Y; Takeuchi M
    J Clin Pharmacol; 2011 Apr; 51(4):549-60. PubMed ID: 20628171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs and indications in 2013: little real progress but regulatory authorities take some positive steps.
    Prescrire Int; 2014 Apr; 23(148):107-10. PubMed ID: 24860905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An FDA oncology analysis of antibody-drug conjugates.
    Saber H; Leighton JK
    Regul Toxicol Pharmacol; 2015 Apr; 71(3):444-52. PubMed ID: 25661711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children.
    Vinks AA; Emoto C; Fukuda T
    Clin Pharmacol Ther; 2015 Sep; 98(3):298-308. PubMed ID: 26073179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of factors associated with dose differences between Japan and the United States.
    Arnold FL; Fukunaga S; Kusama M; Matsuki N; Ono S
    Clin Pharmacol Ther; 2014 May; 95(5):542-9. PubMed ID: 24281222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Survey of Neonatal Pharmacokinetic and Pharmacodynamic Studies in Pediatric Drug Development.
    Wang J; Avant D; Green D; Seo S; Fisher J; Mulberg AE; McCune SK; Burckart GJ
    Clin Pharmacol Ther; 2015 Sep; 98(3):328-35. PubMed ID: 25975723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Before crushing a tablet or opening a capsule...
    Prescrire Int; 2014 Sep; 23(152):211. PubMed ID: 25325121
    [No Abstract]   [Full Text] [Related]  

  • 11. Failed Pediatric Drug Development Trials.
    Momper JD; Mulugeta Y; Burckart GJ
    Clin Pharmacol Ther; 2015 Sep; 98(3):245-51. PubMed ID: 25963725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies and Recommendations for Using a Data-Driven and Risk-Based Approach in the Selection of First-in-Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment.
    Leach MW; Clarke DO; Dudal S; Han C; Li C; Yang Z; Brennan FR; Bailey WJ; Chen Y; Deslandes A; Loberg LI; Mayawala K; Rogge MC; Todd M; Chemuturi NV
    Clin Pharmacol Ther; 2021 Jun; 109(6):1395-1415. PubMed ID: 32757299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric microdose and microtracer studies using 14C in Europe.
    Turner MA; Mooij MG; Vaes WH; Windhorst AD; Hendrikse NH; Knibbe CA; Kõrgvee LT; Maruszak W; Grynkiewicz G; Garner RC; Tibboel D; Park BK; de Wildt SN
    Clin Pharmacol Ther; 2015 Sep; 98(3):234-7. PubMed ID: 26095095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selecting the proper pediatric dose: It is more than size that matters.
    Kearns GL
    Clin Pharmacol Ther; 2015 Sep; 98(3):238-40. PubMed ID: 26073060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
    Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drugs and indications in 2014. Some advances this year, but many drugs are poorly evaluated, too expensive, or more dangerous than useful.
    Prescrire Int; 2015 Apr; 24(159):107-10. PubMed ID: 25941710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring differences in drug doses between Japan and Western countries.
    Arnold FL; Kusama M; Ono S
    Clin Pharmacol Ther; 2010 Jun; 87(6):714-20. PubMed ID: 20410879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neonatal drug therapy: The first frontier of therapeutics for children.
    Allegaert K; van den Anker J
    Clin Pharmacol Ther; 2015 Sep; 98(3):288-97. PubMed ID: 26095519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nonclinical safety assessment of MnTE-2-PyP, a manganese porphyrin.
    Gad SC; Sullivan DW; Crapo JD; Spainhour CB
    Int J Toxicol; 2013 Jul; 32(4):274-87. PubMed ID: 23704100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.